GlobeImmune (OTCMKTS:GBIM) Shares Down 39.5%

GlobeImmune Inc (OTCMKTS:GBIM) shares were down 39.5% during mid-day trading on Friday . The stock traded as low as $0.06 and last traded at $0.06, approximately 2,001 shares traded hands during trading. A decline of 79% from the average daily volume of 9,682 shares. The stock had previously closed at $0.10.

The stock has a fifty day moving average of $0.11.

About GlobeImmune (OTCMKTS:GBIM)

GlobeImmune, Inc, a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy.

Featured Article: Consumer behavior in bull markets

Receive News & Ratings for GlobeImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeImmune and related companies with MarketBeat.com's FREE daily email newsletter.